If you've looked into testosterone replacement therapy, you've probably run across conflicting headlines: one study raises alarms about heart attacks, another says testosterone therapy is safe for the heart. Both threads trace back to real events in the medical literature, but neither tells the whole story on its own.
This is patient education, not medical advice. Only an independent licensed medical professional can evaluate your personal cardiovascular history and determine whether testosterone therapy is appropriate for you.
Why cardiovascular risk questions come up with testosterone therapy
Testosterone's effects reach beyond reproductive health. It influences red blood cell production, cholesterol particles, and fluid balance, all systems that also matter for cardiovascular health. That overlap is a large part of why researchers have spent well over a decade studying whether raising testosterone levels changes a person's risk of heart attack or stroke.
The other part of the story is timing. Many people who consider testosterone therapy are in an age range, roughly the 40s through 60s, where cardiovascular risk factors such as high blood pressure, elevated cholesterol, and reduced physical activity are becoming more common on their own, independent of testosterone. Separating what testosterone itself contributes from what a person already carried into treatment has taken years of dedicated research, and it's still an active area of study.
What the FDA's 2015 labeling change said and why
In 2015, the FDA required manufacturers of all prescription testosterone products to update their labeling, and two changes stood out. First, the agency clarified that these products are approved for men who have low testosterone caused by specific medical conditions affecting the testicles, pituitary gland, or brain, not for a general decline in testosterone that can come with age alone. Second, labeling was required to describe a possible increased risk of heart attack and stroke associated with testosterone use, reflecting studies available at the time.
Alongside that labeling change, the FDA required manufacturers to conduct further studies specifically designed to evaluate cardiovascular safety. That requirement mattered because the earlier studies that prompted the FDA's action had real limitations: some were observational rather than randomized, and their findings didn't consistently point in the same direction. The FDA's response was not to declare the question settled, but to require both a cautious label and better evidence going forward.
What more recent research has shown
In the years since, larger and more rigorously designed clinical trials have added meaningfully to the picture. The Endocrine Society has noted that more recent large clinical trials, conducted specifically to evaluate cardiovascular outcomes, found that testosterone therapy in appropriately selected men with confirmed low testosterone, treated and monitored under clinical supervision, was not associated with a higher rate of major cardiovascular events, such as heart attack, stroke, or cardiovascular death, compared with placebo.
That's a meaningfully more reassuring picture than the caution built into the 2015 label alone might suggest, for that specific outcome, in that particular population. It doesn't mean the question is closed. Research continues, including work looking at specific subgroups, formulations, and longer-term outcomes, and clinicians and researchers keep reviewing new data as it's published. It's also worth being precise about scope: this evolving, more reassuring evidence applies to men with a confirmed diagnosis of low testosterone who are treated and monitored appropriately, not to unsupervised or off-label use in people without that diagnosis.
Two things can both be true
The FDA's 2015 caution reflected real limitations in the evidence available at that time. Newer, larger trials have since been more reassuring for major cardiovascular events in appropriately selected, monitored patients. Neither fact cancels the other out, and both inform how TRT is evaluated and monitored today.
Who needs extra caution before starting TRT
Because testosterone can influence factors relevant to cardiovascular health, a personal or family history of certain conditions is something a clinician weighs carefully during an evaluation. This typically includes:
- A personal history of heart attack, stroke, or blood clots
- Uncontrolled high blood pressure
- Known heart disease or heart failure
- A history of blood clotting disorders
- Untreated severe sleep apnea, which testosterone can sometimes worsen
None of these automatically rules out treatment, but they change the conversation. A clinician may recommend addressing or stabilizing a cardiovascular condition first, choosing a particular formulation, or monitoring more closely once treatment starts. This is exactly the kind of individualized judgment call that makes a licensed clinician's evaluation, rather than a generic answer, the appropriate starting point.
How cardiovascular risk is monitored during treatment
Ongoing monitoring is a standard part of responsible TRT management, and much of it connects directly to cardiovascular health. Blood pressure is checked periodically, since testosterone can affect fluid balance, and unmanaged high blood pressure is itself a cardiovascular risk factor.
Hematocrit, a measure of red blood cell concentration, is also checked with routine blood work. Testosterone can increase red blood cell production, and if hematocrit climbs too high, blood can become thicker, which is itself a cardiovascular consideration and something a clinician may address by adjusting the dose, changing the formulation, or spacing out treatment intervals. Lipid levels are sometimes monitored as well, since cholesterol particles can shift somewhat during treatment. None of this monitoring is an optional add-on; it's part of how TRT is intended to be managed responsibly over time.
Talking to a clinician about your personal risk
The honest summary of where the research stands today is this: the FDA's 2015 label reflects real caution that was appropriate given the evidence available at the time, and more recent large trials have been reassuring for major cardiovascular events in appropriately selected, monitored patients, while research continues to refine the picture for specific groups. Neither the older caution nor the newer reassurance is the whole story by itself.
What that means in practice is that your personal cardiovascular risk with testosterone therapy isn't something a website can answer generically. It depends on your age, your existing cardiovascular risk factors, your family history, and how any treatment would be dosed and monitored. That's precisely the assessment a licensed clinician makes during an evaluation, and it's why testosterone therapy is treated as a prescription decision rather than a one-size-fits-all wellness purchase.
To learn more about the basics, read our overview of what testosterone replacement therapy is, and see how TRT is prescribed and monitored for more on the evaluation and follow-up process. Our piece on long-term outcomes of TRT covers what ongoing therapy looks like more broadly, and cardiovascular risk shows up in a related way in our explainer on erectile dysfunction and heart health. You can browse more explainers in our Testosterone category.
The bottom line
In 2015, the FDA required testosterone product labeling to describe a possible increased risk of heart attack and stroke and asked manufacturers to study cardiovascular safety further. Since then, larger clinical trials reviewed by the Endocrine Society have found that testosterone therapy in appropriately selected, monitored men with confirmed low testosterone was not associated with a higher rate of major cardiovascular events compared with placebo, though research continues to evolve. Cardiovascular history is a key part of any TRT evaluation, and ongoing monitoring, including blood pressure and hematocrit checks, is a standard part of responsible treatment. Whether TRT is appropriate for you, and how it should be monitored, is a decision made individually with a licensed clinician.
Important Safety Information
Indication. Testosterone replacement therapy is FDA-approved to treat adult men with low testosterone caused by specific medical conditions that affect the testicles, pituitary gland, or brain and reduce the body's natural testosterone production; it is not FDA-approved simply for a decline in testosterone associated with aging alone.
Common side effects. Acne or oily skin, injection-site or application-site reactions, fluid retention, increased red blood cell count, and breast tenderness or enlargement have been reported.
Warnings. Testosterone product labeling describes a possible increased risk of heart attack and stroke. Testosterone should not be used in men with breast cancer or known or suspected prostate cancer, and it may worsen symptoms of benign prostatic hyperplasia, increase red blood cell counts requiring monitoring, and worsen sleep apnea in some people. Topical testosterone products carry warnings about the potential for secondary exposure to testosterone in children and women through skin contact.
Talk to your doctor. This information is educational and is not a substitute for medical advice. Only a licensed medical professional can determine whether a treatment is right for you. Talk to your doctor about the benefits and risks, and report any side effects.
Frequently asked questions
Does testosterone therapy increase the risk of a heart attack?
The evidence has evolved. In 2015, the FDA required testosterone labeling to describe a possible increased risk of heart attack and stroke, based on studies available at the time. More recent large clinical trials have found that testosterone therapy in appropriately selected, monitored men was not associated with a higher rate of major cardiovascular events compared with placebo, though research in this area continues. Your personal risk depends on individual factors a clinician evaluates directly.
Why did the FDA change testosterone labeling in 2015?
The FDA required the labeling change after studies suggested a possible increased cardiovascular risk associated with testosterone use. At the same time, the FDA clarified that testosterone products are approved for men with low testosterone from specific medical conditions, not age-related decline alone, and required manufacturers to conduct further studies on cardiovascular safety.
Who should be especially cautious about testosterone therapy because of heart health?
People with a personal history of heart attack, stroke, or blood clots, uncontrolled high blood pressure, known heart disease, or untreated severe sleep apnea typically need a more careful evaluation before starting TRT. These histories don't automatically rule out treatment, but they change how a clinician approaches the decision and any monitoring plan.
What monitoring happens for heart-related risk during TRT?
Clinicians typically check blood pressure and hematocrit, a measure of red blood cell concentration, periodically during treatment. Testosterone can raise red blood cell counts, which is a cardiovascular consideration if it rises too high, and blood pressure changes are also tracked. Lipid levels are sometimes monitored as well.
Can testosterone therapy affect cholesterol or blood pressure?
Testosterone therapy can affect cholesterol particles and fluid balance in ways that vary between individuals. This is one reason routine monitoring is part of standard TRT management, and it's a factor your clinician weighs alongside your broader cardiovascular history when starting and adjusting treatment.
